Roquefort Therapeutics (ROQ) Competitors GBX 3.92 +0.02 (+0.59%) (As of 12/20/2024 11:17 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider Trades ROQ vs. OKYO, OPTI, OBI, AOR, RLM, NSCI, ONC, SNG, BVX, and APTAShould you be buying Roquefort Therapeutics stock or one of its competitors? The main competitors of Roquefort Therapeutics include OKYO Pharma (OKYO), OptiBiotix Health (OPTI), Ondine Biomedical (OBI), AorTech International (AOR), Realm Therapeutics (RLM), NetScientific (NSCI), Oncimmune (ONC), Synairgen (SNG), BiVictriX Therapeutics (BVX), and Aptamer Group (APTA). These companies are all part of the "biotechnology" industry. Roquefort Therapeutics vs. OKYO Pharma OptiBiotix Health Ondine Biomedical AorTech International Realm Therapeutics NetScientific Oncimmune Synairgen BiVictriX Therapeutics Aptamer Group Roquefort Therapeutics (LON:ROQ) and OKYO Pharma (LON:OKYO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, community ranking, valuation, media sentiment, earnings and analyst recommendations. Which has more volatility and risk, ROQ or OKYO? Roquefort Therapeutics has a beta of 0.05, meaning that its share price is 95% less volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500. Is ROQ or OKYO more profitable? Roquefort Therapeutics' return on equity of -27.05% beat OKYO Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Roquefort TherapeuticsN/A -27.05% -15.86% OKYO Pharma N/A -397.13%-154.72% Does the MarketBeat Community favor ROQ or OKYO? OKYO Pharma received 7 more outperform votes than Roquefort Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformRoquefort TherapeuticsN/AN/AOKYO PharmaOutperform Votes763.64% Underperform Votes436.36% Which has better valuation and earnings, ROQ or OKYO? Roquefort Therapeutics has higher revenue and earnings than OKYO Pharma. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than OKYO Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoquefort Therapeutics£637.007,953.77-£1.54M-£0.01-392.30OKYO PharmaN/AN/A-£6.70M-£0.01N/A Do institutionals and insiders believe in ROQ or OKYO? 1.7% of Roquefort Therapeutics shares are held by institutional investors. 60.4% of Roquefort Therapeutics shares are held by insiders. Comparatively, 31.9% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer ROQ or OKYO? In the previous week, Roquefort Therapeutics and Roquefort Therapeutics both had 1 articles in the media. Roquefort Therapeutics' average media sentiment score of 0.75 beat OKYO Pharma's score of 0.00 indicating that Roquefort Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roquefort Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OKYO Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryRoquefort Therapeutics beats OKYO Pharma on 8 of the 10 factors compared between the two stocks. Ad Porter & CompanyHow to piss off your liberal friends… and profit from itElon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Roquefort Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ROQ vs. The Competition Export to ExcelMetricRoquefort TherapeuticsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£5.07M£165.68M£5.14B£1.92BDividend YieldN/A3.64%5.09%5.45%P/E Ratio-392.30115.5189.971,880.82Price / Sales7,953.7718,531.021,116.34397,035.90Price / Cash1.4912.8743.1028.78Price / Book0.988.594.782.81Net Income-£1.54M-£20.67M£120.31M£156.11M7 Day Performance-12.82%-1.05%-1.92%-2.03%1 Month Performance-4.78%174.77%13.65%21.85%1 Year Performance-45.89%134.18%28.34%30.10% Roquefort Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ROQRoquefort TherapeuticsN/AGBX 3.92+0.6%N/A-45.9%£5.07M£637.00-392.309OKYOOKYO PharmaN/AGBX 1.40-24.3%N/AN/A£23.24MN/A-140.007News CoverageGap DownOPTIOptiBiotix HealthN/AGBX 22.60+6.6%N/A-26.9%£22.13M£1.26M-753.331High Trading VolumeOBIOndine BiomedicalN/AGBX 7.75+2.0%N/A-6.2%£21.49M£1.63M-258.33N/AAORAorTech InternationalN/AN/AN/AN/A£19.99M£539,000.00-33.383RLMRealm TherapeuticsN/AGBX 11.50flatN/AN/A£13.41M£501,919.00-0.66N/ANSCINetScientificN/AGBX 53.50flatN/AN/A£12.81M£1.45M-486.3626ONCOncimmuneN/AGBX 15.85+1.3%N/A-41.3%£11.75M£1.21M-528.3352SNGSynairgenN/AGBX 4.38-0.2%N/A-70.1%£8.82M£79,000.00-144.7334Gap DownBVXBiVictriX TherapeuticsN/AGBX 10+17.6%N/AN/A£8.25MN/A-250.0017Gap UpHigh Trading VolumeAPTAAptamer GroupN/AN/AN/A-69.6%£8.06M£1.03M-4.7837Positive NewsHigh Trading Volume Related Companies and Tools Related Companies OKYO Alternatives OPTI Alternatives OBI Alternatives AOR Alternatives RLM Alternatives NSCI Alternatives ONC Alternatives SNG Alternatives BVX Alternatives APTA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:ROQ) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThis is the worst sign for the U.S. stock market in 50 yearsThe Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts no...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roquefort Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Roquefort Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ROQ Stock Alerts